Myocardium; InjuryNCT06211244
Association of Serum Eotaxin Levels and Markers of Myocardiac Injury in Hemodialysis Patients
An observational study of Myocardium; Injury and Coronary Artery Disease, run by Tungs' Taichung Metroharbour Hospital at 1 site in Taiwan.
Trial summary
Background: Cardiovascular disease (CVD) is one of the leading causes of morbidity and mortality among dialysis patients. Eotaxin-1(also known as Eotaxin and CCL11), an eosinophil-specific chemoattractant that plays a role in a variety of pathologic conditions including allergy, coronary heart disease, and… Read more about this study
- Who is it for?
- Ages 20 years and older
- Conditions the study is for
- Myocardium; Injury, Coronary Artery Disease
- How many people
- 291 participants
- Where
- 1 siteTaiwan
- Study dates
- 2 May 2024to 31 Dec 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: patients have to be at least 20-years-old and on outpatient hemodialysis (HD) for at least 3 months.
Who may be able to join
- Both sexes aged 20 years or over
- Received stable hemodialysis at least 3 months.
- Written informed consent.
Who cannot join
- acute infection or malignancy
Trial locations and contacts
1 site in 1 country.
About this study
Background:
Cardiovascular disease (CVD) is one of the leading causes of morbidity and mortality among dialysis patients. Eotaxin-1(also known as Eotaxin and CCL11), an eosinophil-specific chemoattractant that plays a role in a variety of pathologic conditions including allergy, coronary heart disease, and inflammatory bowel disease. CCL11 has been shown to be overexpressed in human atherosclerotic lesions. Moreover, eotaxin-1 levels are higher in non-uremic coronary artery disease patients than in healthy individuals.
Read more
Methods:
The study will enrolled 400 hemodialysis patients. Patients are diagnosed with coronary artery disease based on clinical presentation and confirmed by angiography. Serum eotaxin-1 and 8-isoprostane levels are determined by enzyme-linked immunosorbent assay (ELISA). High-sensitivity cTnI immunoassays and albumin redox state by high-performance liquid chromatography are used for measurements.
Aim:
In this study, we aimed to determine the eotaxin-1 concentrations of patients with coronary artery disease and to investigate the role of eotaxin-1 and markers of myocardial injury.
Read the detailed description
Study Design and Patient Population This cross-sectional trial, and will be carried out in accordance with the Declaration of Helsinki and applicable regulations. The protocol will be sent to the institutional ethics committee and patients' written informed consent will be obtained. To be included in the study, patients will be at least 20-years-old and on outpatient HD for at least 3 months. All the patients were dialyzed three times a week with a high-flux membrane and bicarbonate dialysate solutions. Patients will excluded if they had an acute infection or malignancy. A total of 400 long-term HD patients are randomly invited and enrolled in the study. The medical records will thoroughly reviewed for each subject by a collaborating physician in the study. Information such as underlying kidney disease, cardiovascular disease history, and other comorbid illnesses are abstracted. A pre-existing history of CVD was defined as a history of CAD ( including a history of myocardial infarction, coronary artery angioplasty/stenting/bypass surgery, carotid endarterectomy/stenting), cerebrovascular disease (CVD, e.g., stroke), non-traumatic lower extremity amputation, and lower limb artery bypass surgery/angioplasty/stenting
Measurements Predialysis blood samples are obtained on a mid-week day.Within 30 min after sampling, the remaining blood arecentrifuged at 3,000 g for 10 min, immediately aliquoted and frozen at-80 °C until further analysis. The total serum cholesterol is measured through the reaction of cholesterol esterase/cholesterol oxidase/peroxidase, using Hitachi 747 (Hitachi, Bohemia, NY, USA). HDL cholesterol is quantified after precipitation with polyethylene glycol at room temperature. Serum glucose concentrations are measured by the glucose oxidase method. Low-density lipoprotein cholesterol was calculated using the Friedewald formula. Total serum triglycerides were measured through the reaction of glycerol/ phosphate/oxidase and peroxidase. The serum levels of high-sensitivity C-reactive protein (hsCRP) are measured using a Behring Nephelometer II (Dade Behring, Tokyo, Japan). Serum levels of IL-6 and MCP-1 are measured by a commercially available enzyme-linked immunosorbent assay (Quantikine HS Immunoassaykit, R\&D System, Minneapolis, MN, USA). Serum 8-isoprostane concentrations were measured using the ELISA assay (Cayman Chemical, Ann Arbor, Michigan, USA) with a detection limit of 3 pg/mL, according to the manufacturer's instruction.
Serum eotaxin levels will be determined using a commercial ELISA kit (R\&D systems, Minneapolis, MN, USA)according to the manufacturer's protocol. In brief, mouse antihuman antibody against eotaxin is used to capture eotaxin from plasma. Captured eotaxin is detected with biotynilated goat antihuman eotaxin antibody. After washing, plates are incubated with streptavidin-HRP, developed with appropriate substrate, and OD450 is determined using an ELISA plate reader. Measurements are done in duplicate in an assay able to detect 10 pg of eotaxin/ml. The intraand inter-assay coefficients of variation values are <4% and <6%, respectively.
The Siemens Atellica IM High Sensitivity Troponin I assay (Siemens Healthineers) is a three-site sandwich immunoassay with a limit of detection of 1.6 ng/L and limit of quantification of 2.5 ng/L. The upper reference limit 99th centile was determined in 2007 samples from healthy individuals as 34 ng/L in women, and 53 ng/L in men, with a single threshold of 45 ng/L. In the reference range population, 75% of patients had values greater than the limit of detection. All measurements were undertaken at a central laboratory, who were blinded to all clinical information with results provided to the research team and linked to the trial database for analysis.
The redox state of serum albumin was determined by fractionating it into human mercaptalbumin (HMA), human nonmercaptalbumin-1 (HNA-1), and human non-mercaptalbumin-2 (HNA-2) with high-performance liquid chromatography (HPLC).
- Conditions
- Myocardium; Injury, Coronary Artery Disease
- Keywords
- coronary artery disease, Eotaxin-1, hemodialysis patients, myocardial injury
- Medical subject headings
- Wounds and Injuries, Coronary Artery Disease
What is being measured
The primary outcome is the main question the study is designed to answer.
Analysis of biomarkers of serum eotaxin levels.
Eotaxin levels and the serum levels of markers of myocardial injury as well as oxidative stress in a group of prevalent hemodialysis patients.
Measured: 1 years
Secondary outcomes (5)
Redox state of serum albumin assays
The redox state of albumin was determined from serum samples with high-performance liquid chromatography
Measured: 1 years
Analysis of biomarkers of MCP-1
The MCP-1 was determined from serum samples using standardized enzymelinked immunosorbent assay (ELISA) methods
Measured: 1 years
Analysis of biomarkers of IL-6
The IL-6 was determined from serum samples using standardized enzymelinked immunosorbent assay (ELISA) methods
Measured: 1 years
Analysis of biomarkers of 8-isoprostane
The 8-isoprostane was determined from serum samples using standardized enzymelinked immunosorbent assay (ELISA) methods
Measured: 1 years
Analysis of biomarkers of High Sensitivity Troponin I
The Siemens Atellica IM High Sensitivity Troponin I assay (Siemens Healthineers) is a three-site sandwich immunoassay with a limit of detection of 1.6 ng/L and limit of quantification of 2.5 ng/L.
Measured: 1 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Jan 2024
- Study start2 May 2024
- Primary completion31 Dec 2024
- Study completion31 Dec 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Myocardium; InjuryStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 291 participants (actual)
Sponsor and investigators
- Lead sponsor
- Tungs' Taichung Metroharbour Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Paik Seong Lim, PhD, Principal investigator, Tungs' Taichung Metroharbour Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06211244
- Sponsor's protocol ID
- 112062
- Status last verified
- Jun 2025
- First submitted
- 8 Jan 2024
- Last updated
- 6 Jun 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 6 Jun 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Association of Serum Eotaxin Levels and Markers of Myocardiac Injury in Hemodialysis Patients
- ClinicalTrials.gov ID
- NCT06211244
- Acronym / sponsor ID
- 112062
- Conditions
- Myocardium; Injury, Coronary Artery Disease
- Keywords
- coronary artery disease, Eotaxin-1, hemodialysis patients, myocardial injury
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 291 participants (actual)
- Lead sponsor
- Tungs' Taichung Metroharbour HospitalUniversity, hospital or other
- Study start
- 2 May 2024 (actual)
- Primary completion
- 31 Dec 2024 (actual)
- Study completion
- 31 Dec 2024 (actual)
- First posted
- 18 Jan 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Background:
Cardiovascular disease (CVD) is one of the leading causes of morbidity and mortality among dialysis patients. Eotaxin-1(also known as Eotaxin and CCL11), an eosinophil-specific chemoattractant that plays a role in a variety of pathologic conditions including allergy, coronary heart disease, and inflammatory bowel disease. CCL11 has been shown to be overexpressed in human atherosclerotic lesions. Moreover, eotaxin-1 levels are higher in non-uremic coronary artery disease patients than in healthy individuals.
Methods:
The study will enrolled 400 hemodialysis patients. Patients are diagnosed with coronary artery disease based on clinical presentation and confirmed by angiography. Serum eotaxin-1 and 8-isoprostane levels are determined by enzyme-linked immunosorbent assay (ELISA). High-sensitivity cTnI immunoassays and albumin redox state by high-performance liquid chromatography are used for measurements.
Aim:
In this study, we aimed to determine the eotaxin-1 concentrations of patients with coronary artery disease and to investigate the role of eotaxin-1 and markers of myocardial injury.
Detailed description
Study Design and Patient Population This cross-sectional trial, and will be carried out in accordance with the Declaration of Helsinki and applicable regulations. The protocol will be sent to the institutional ethics committee and patients' written informed consent will be obtained. To be included in the study, patients will be at least 20-years-old and on outpatient HD for at least 3 months. All the patients were dialyzed three times a week with a high-flux membrane and bicarbonate dialysate solutions. Patients will excluded if they had an acute infection or malignancy. A total of 400 long-term HD patients are randomly invited and enrolled in the study. The medical records will thoroughly reviewed for each subject by a collaborating physician in the study. Information such as underlying kidney disease, cardiovascular disease history, and other comorbid illnesses are abstracted. A pre-existing history of CVD was defined as a history of CAD ( including a history of myocardial infarction, coronary artery angioplasty/stenting/bypass surgery, carotid endarterectomy/stenting), cerebrovascular disease (CVD, e.g., stroke), non-traumatic lower extremity amputation, and lower limb artery bypass surgery/angioplasty/stenting
Measurements Predialysis blood samples are obtained on a mid-week day.Within 30 min after sampling, the remaining blood arecentrifuged at 3,000 g for 10 min, immediately aliquoted and frozen at-80 °C until further analysis. The total serum cholesterol is measured through the reaction of cholesterol esterase/cholesterol oxidase/peroxidase, using Hitachi 747 (Hitachi, Bohemia, NY, USA). HDL cholesterol is quantified after precipitation with polyethylene glycol at room temperature. Serum glucose concentrations are measured by the glucose oxidase method. Low-density lipoprotein cholesterol was calculated using the Friedewald formula. Total serum triglycerides were measured through the reaction of glycerol/ phosphate/oxidase and peroxidase. The serum levels of high-sensitivity C-reactive protein (hsCRP) are measured using a Behring Nephelometer II (Dade Behring, Tokyo, Japan). Serum levels of IL-6 and MCP-1 are measured by a commercially available enzyme-linked immunosorbent assay (Quantikine HS Immunoassaykit, R\&D System, Minneapolis, MN, USA). Serum 8-isoprostane concentrations were measured using the ELISA assay (Cayman Chemical, Ann Arbor, Michigan, USA) with a detection limit of 3 pg/mL, according to the manufacturer's instruction.
Serum eotaxin levels will be determined using a commercial ELISA kit (R\&D systems, Minneapolis, MN, USA)according to the manufacturer's protocol. In brief, mouse antihuman antibody against eotaxin is used to capture eotaxin from plasma. Captured eotaxin is detected with biotynilated goat antihuman eotaxin antibody. After washing, plates are incubated with streptavidin-HRP, developed with appropriate substrate, and OD450 is determined using an ELISA plate reader. Measurements are done in duplicate in an assay able to detect 10 pg of eotaxin/ml. The intraand inter-assay coefficients of variation values are <4% and <6%, respectively.
The Siemens Atellica IM High Sensitivity Troponin I assay (Siemens Healthineers) is a three-site sandwich immunoassay with a limit of detection of 1.6 ng/L and limit of quantification of 2.5 ng/L. The upper reference limit 99th centile was determined in 2007 samples from healthy individuals as 34 ng/L in women, and 53 ng/L in men, with a single threshold of 45 ng/L. In the reference range population, 75% of patients had values greater than the limit of detection. All measurements were undertaken at a central laboratory, who were blinded to all clinical information with results provided to the research team and linked to the trial database for analysis.
The redox state of serum albumin was determined by fractionating it into human mercaptalbumin (HMA), human nonmercaptalbumin-1 (HNA-1), and human non-mercaptalbumin-2 (HNA-2) with high-performance liquid chromatography (HPLC).
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
Who may qualify
- Ages
- 20 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- patients have to be at least 20-years-old and on outpatient hemodialysis (HD) for at least 3 months.
Key inclusion criteria (3 listed)
- Both sexes aged 20 years or over
- Received stable hemodialysis at least 3 months.
- Written informed consent.
Key exclusion criteria (1 listed)
- acute infection or malignancy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Analysis of biomarkers of serum eotaxin levels.
Time frame: 1 years
Eotaxin levels and the serum levels of markers of myocardial injury as well as oxidative stress in a group of prevalent hemodialysis patients.
5 secondary outcomes
Redox state of serum albumin assays
Time frame: 1 years
Analysis of biomarkers of MCP-1
Time frame: 1 years
Analysis of biomarkers of IL-6
Time frame: 1 years
Analysis of biomarkers of 8-isoprostane
Time frame: 1 years
Analysis of biomarkers of High Sensitivity Troponin I
Time frame: 1 years
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Jun 2025.
- Individual participant dataSharing planned: No
Related trials for Myocardium; Injury
Not yet recruitingPhase 4
Roxadustat and Myocardial Injury After Off-Pump Coronary Artery Bypass Surgery
Coronary Artery Disease, Coronary Artery Bypass Grafting
RecruitingObservational study
Mechanisms of Myocardial Injury and Ischemia in Patients With Rapid Atrial Fibrillation
Atrial Fibrillation (AF)
Recruiting
CRP Apheresis in STEMI
ST Elevation Myocardial Infarction, C-Reactive Protein
Not yet recruitingObservational study
High-Sensitivity Troponin T Kinetics and 30-Day Outcomes After Major Abdominal Surgery (TROP-MAS)
Myocardial Infarction (MI), Perioperative Myocardial Injury
Not yet recruiting
Intranasal Dexmedetomidine and Perioperative Myocardial Injury in Patients Having Percutaneous Coronary Interventions
Coronary Heart Disease, Coronary Artery Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Paik Seong Lim, PhD principal investigator
Tungs' Taichung Metroharbour Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Myocardium; Injury and Coronary Artery Disease, run by Tungs' Taichung Metroharbour Hospital at 1 site in Taiwan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 6 Jun 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Analysis of biomarkers of serum eotaxin levels. (time frame: 1 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Jun 2025.